- Home
- BILL vs PCVX Comparison
BILL vs PCVX Comparison
Compare BILL & PCVX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BILL
- PCVX
- Stock Information
- Founded
- BILL 2006
- PCVX 2013
- Country
- BILL United States
- PCVX United States
- Employees
- BILL N/A
- PCVX N/A
- Industry
- BILL EDP Services
- PCVX Biotechnology: Pharmaceutical Preparations
- Sector
- BILL Technology
- PCVX Health Care
- Exchange
- BILL Nasdaq
- PCVX Nasdaq
- Market Cap
- BILL 4.3B
- PCVX 4.5B
- IPO Year
- BILL 2019
- PCVX 2020
- Fundamental
- Price
- BILL $44.66
- PCVX $31.16
- Analyst Decision
- BILL Buy
- PCVX Strong Buy
- Analyst Count
- BILL 19
- PCVX 10
- Target Price
- BILL $65.82
- PCVX $136.50
- AVG Volume (30 Days)
- BILL 1.7M
- PCVX 2.2M
- Earning Date
- BILL 05-08-2025
- PCVX 05-07-2025
- Dividend Yield
- BILL N/A
- PCVX N/A
- EPS Growth
- BILL N/A
- PCVX N/A
- EPS
- BILL N/A
- PCVX N/A
- Revenue
- BILL $1,422,885,000.00
- PCVX N/A
- Revenue This Year
- BILL $15.72
- PCVX N/A
- Revenue Next Year
- BILL $14.20
- PCVX N/A
- P/E Ratio
- BILL N/A
- PCVX N/A
- Revenue Growth
- BILL 14.52
- PCVX N/A
- 52 Week Low
- BILL $36.55
- PCVX $27.66
- 52 Week High
- BILL $100.19
- PCVX $121.06
- Technical
- Relative Strength Index (RSI)
- BILL 48.05
- PCVX 36.73
- Support Level
- BILL $44.02
- PCVX $28.09
- Resistance Level
- BILL $46.84
- PCVX $33.75
- Average True Range (ATR)
- BILL 1.82
- PCVX 2.54
- MACD
- BILL 0.57
- PCVX 1.12
- Stochastic Oscillator
- BILL 51.35
- PCVX 35.61
About BILL BILL Holdings Inc.
BILL Holdings Inc is a provider of software-as-a-service, cloud-based payments and spend and expense management products, which allow users to automate accounts payable and accounts receivable transactions, enable businesses to easily connect with their suppliers or customers to do business, eliminate expense reports, manage cash flows and improve back office efficiency. Initial Public Offering and Follow-on Offering.
About PCVX Vaxcyte Inc.
Vaxcyte Inc is a clinical-stage vaccine innovation company engineering high-fidelity vaccines to protect humankind from the consequences of bacterial diseases. It is developing broad-spectrum conjugate and novel protein vaccines to prevent or treat bacterial infectious diseases. Its product comprises of Pneumococcal conjugate vaccine. The firm's product candidate consists of VAX-31, VAX-24, VAX-A1, VAX-PG, VAX-GI, and Others.